India Pneumococcal Vaccine Market By Vaccine Type (Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine), By End Use (Public Sector, Private Sector), By Region, Competition, Forecast & Opportunities, 2020-2030F

The Indian Pneumococcal Vaccine Market was valued at USD 32.52 million in 2024 and is projected to reach USD 48.67 million by 2030, registering a compound annual growth rate (CAGR) of 6.91% during the forecast period. The market is experiencing robust growth driven by government initiatives, an increasing disease burden, and the expansion of healthcare infrastructure. A significant growth factor is the inclusion of the Pneumococcal Conjugate Vaccine (PCV) in the Universal Immunization Programme (UIP), which has resulted in broader vaccine coverage, particularly in high-burden states like Uttar Pradesh, Bihar, and Maharashtra. Additionally, rising awareness of pneumonia-related mortality, especially among children, has further fueled vaccine adoption. The presence of major domestic manufacturers, such as Serum Institute of India and Bharat Biotech, has improved vaccine affordability and availability, reducing reliance on imports. Furthermore, international organizations like Gavi, WHO, and UNICEF have played a pivotal role in expanding vaccine accessibility to rural and underserved areas. However, challenges remain, including low adult vaccination rates, as pneumococcal vaccines are generally perceived to be for children. The uptake of Pneumococcal Polysaccharide Vaccine (PPSV) is also limited, largely due to a lack of awareness among high-risk adult groups, such as the elderly and individuals with chronic conditions. Additionally, distribution challenges in remote regions hinder vaccine delivery, despite efforts to enhance last-mile logistics. Vaccine hesitancy, driven by misinformation and insufficient education in rural areas, further impedes adoption. Nonetheless, India's pneumococcal vaccine market is set for continued growth, supported by increased public health investments, expanding private sector participation, and advancements in domestic vaccine production.

Key Market Drivers

Rising Geriatric Population

India's rapidly growing elderly population is a key driver for the pneumococcal vaccine market, as individuals aged 60 and above are particularly susceptible to pneumococcal infections, including pneumonia, sepsis, and meningitis. India currently has approximately 153 million elderly citizens, a number projected to rise to 347 million by 2050, highlighting the growing demand for preventive healthcare solutions, including vaccines. As aging individuals are more vulnerable to severe respiratory infections due to a weakened immune system, pneumococcal vaccination has become an essential preventive measure, helping reduce both disease incidence and the economic burden on the healthcare system.

Key Market Challenges

Low Adult Vaccination Rates

A significant challenge in the Indian pneumococcal vaccine market is the low vaccination rate among adults, particularly high-risk groups such as the elderly and individuals with chronic diseases. While pediatric immunization is well-integrated into the Universal Immunization Programme (UIP), awareness and uptake of adult vaccination remain low. Unlike countries where adult vaccination is a common preventive practice, in India, there is limited awareness about the benefits of pneumococcal vaccines for adults, including those with diabetes, chronic respiratory diseases, and cardiovascular conditions. A major factor contributing to this low adoption is the lack of a national adult immunization program. Furthermore, adult pneumococcal vaccines are typically self-financed, with costs ranging from ₹2,500 to ₹4,500 per dose, making them unaffordable for large segments of the population, especially in private healthcare settings.

Key Market Trends

Increased Research & Development

The Indian pneumococcal vaccine market is experiencing significant growth due to increased research and development (R&D) efforts aimed at improving vaccine efficacy, affordability, and accessibility. With the rising burden of pneumococcal infections and a growing demand for cost-effective, broad-spectrum vaccines, both domestic and international pharmaceutical companies are investing heavily in R&D to develop next-generation pneumococcal vaccines tailored to India's diverse population. A key focus of R&D is on developing vaccines with broader coverage. Current vaccines, such as PCV and PPSV, protect against a limited number of pneumococcal serotypes. However, with over 90 serotypes identified globally, researchers are working on vaccines that offer protection against a wider range of prevalent serotypes in India. Domestic companies like Serum Institute of India (SII) and Bharat Biotech, as well as multinational firms such as Pfizer and Merck, are at the forefront of this development. SII's Pneumosil is a notable example of an affordable, India-specific pneumococcal vaccine.

Key Market Players

• Pfizer Inc.
• Merck & Co. Inc.
• GlaxoSmithKline PLC
• Novartis AG
• Serum Institute of India Pvt. Ltd.
• Panacea Biotec Limited
• Sanofi SA

Report Scope

This report segments the India Pneumococcal Vaccine Market as follows, alongside detailed insights into industry trends:

India Pneumococcal Vaccine Market, by Vaccine Type:

• Pneumococcal Conjugate Vaccine
• Pneumococcal Polysaccharide Vaccine

India Pneumococcal Vaccine Market, by End Use:

• Public Sector
• Private Sector

India Pneumococcal Vaccine Market, by Region:

• East India
• West India
• North India
• South India

Competitive Landscape

Company Profiles:

The report provides an in-depth analysis of the leading companies in the India Pneumococcal Vaccine Market.

Available Customizations:

TechSci Research offers customized reports tailored to specific company needs. The following customization options are available:

• Detailed analysis and profiling of additional market players (up to five).